Kardigan, Inc. (KARD) Fair Value 2026

KARD · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, Kardigan, Inc. (KARD) trades at $20.80. QOC: 3.5/10. Value Trap Risk: 0/100 (SAFE). 0/13 models active.

Key Facts

Ticker
KARD
Price
$20.80
Quality Score
3.5/10
Value Trap Risk
0/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 3.5/10 signals weak fundamentals

What Fair Value Does Each Model Give KARD?

0 Intrinsic Value Models vs. Current Price ($20.80)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Kardigan, Inc. (KARD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Kardigan, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About KARD?

0 of 13 models are currently active for KARD. See which stocks rank higher →

How Does KARD Rank in Biotechnology?

Among 620 Biotechnology stocks, KARD ranks #574 by Quality of Company score. CirclFi's QOC score of 3.5/10 evaluates 32 fundamental signals. A score of 3.5 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Kardigan, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is KARD a Value Trap?

CirclFi's Value Trap algorithm assigns KARD a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Kardigan, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Kardigan, Inc. earns a quality score of 3.5/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KARD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Kardigan, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ZVSAZyVersa Therapeutics, Inc.QOC 3.5ADTXAditxt, Inc.QOC 3.4XCURExicure, Inc.QOC 3.5KLRAKailera Therapeutics, Inc.QOC 3.4HURATuHURA Biosciences, Inc.QOC 3.5LABTLakewood-Amedex Biotherapeutics, Inc.QOC 3.4CTMXCytomX Therapeutics, Inc.QOC 6.3CBUSCibus, Inc.QOC 5.2NTHINeOnc Technologies Holdings, Inc.QOC 4.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ZVSA · ADTX · XCUR · KLRA · HURA · LABT · CTMX · CBUS · NTHI · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to KARD?

5 companies across all industries closest to KARD’s Quality of Company score of 3.5/10.

AADXApplied Aerospace & Defense, Inc.QOC 3.5GCDTGreen Circle Decarbonize TechnoQOC 3.5REARare Earths Americas, Inc.QOC 3.5CSQRCsquare, Inc.QOC 3.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AADX · GCDT · REA · CSQR · NVDA

Where Does KARD Sit in CirclFi's Biotechnology Rankings?

KARD is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Kardigan, Inc.’s Valuation?

What is Kardigan, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Kardigan, Inc. (KARD). The Quality of Company score is 3.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KARD overvalued or undervalued right now?

At $20.80, 0 of 0 active models suggest KARD may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Kardigan, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.5 mean for KARD?

Kardigan, Inc.'s QOC of 3.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on KARD?

CirclFi analyzes KARD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is KARD a value trap in 2026?

Kardigan, Inc.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Kardigan, Inc. (KARD) a Quality of Company score of 3.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/KARD/ · Methodology
Primary sources for this KARD valuation
  • Financial statements: Kardigan, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0002123613) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for KARD as of ; valuations recomputed .